Skip to main content
PMC home page
The AAPS Journal logoLink to The AAPS Journal
. 2006 Sep 1;8(3):E552–E563. doi: 10.1208/aapsj080364

Development and evaluation of a population pharmacokinetic-pharmacodynamic model of darbepoetin alfa in patients with nonmyeloid malignancies undergoing multicycle chemotherapy

Balaji Agoram 1,✉, Anne C Heatherington 1, Marc R Gastonguay 2
PMCID: PMC2761062  PMID: 17025273

Abstract

Anemia is frequently observed in patients undergoing chemotherapy. Administration of darbepoetin alfa, a recombinant erythropoiesis-stimulating agent that has longer residence time than endogenous erythropoietin, to patients with chemotherapy-induced anemia (CIA) increases mean hemoglobin concentration, reduces risk of red blood cell transfusions, and improves patient-reported outcomes. A pharmacokinetic/pharmacodynamic (PkPd) model was developed using data from patients with nonmyeloid malignancies and CIA who were receiving darbepoetin alfa. A 2-compartment Pk model with linear elimination described the Pk data obtained in 140 CIA patients after intravenous and subcutaneous (SC) doses of 2.25 μg/kg every week and SC doses of 6.75 μg/kg every 3 weeks. The population typical values of key Pk parameters were clearance, 2010 mL/day; steady-state volume of distribution, 3390 mL; and bioavailability, 44.3%. A modified indirect response model, wherein serum concentrations stimulated the production of hemoglobin through an Emax-type equation, described the hemoglobin levels after SC doses of 0.5 μg/kg every week to 15 μg/kg every 3 weeks in 573 CIA patients. The estimated incremental maximum stimulation of hemoglobin production was 43.7% and darbepoetin alfa serum concentration at half-maximal stimulation was 3.68 ng/mL. The impact of covariates (body weight and platinum-containing chemotherapy) on the PkPd response was evaluated based on point and interval estimates of parameters, rather than through stepwise hypothesis testing. The final PkPd model adequately predicted hemoglobin response in a test data set, thereby confirming the predictive capability of the model. Based on simulations, it was not possible to categorize the influence of any covariate as clinically important.

Keywords: population PkPd modeling, darbepoetin alfa, covariate analysis

Full Text

The Full Text of this article is available as a PDF (469.2 KB).

References

  • 1.Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst. 1999;91:1616–1634. doi: 10.1093/jnci/91.19.1616. [DOI] [PubMed] [Google Scholar]
  • 2.Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92–98. doi: 10.1056/NEJMoa011954. [DOI] [PubMed] [Google Scholar]
  • 3.Littlewood TJ, Bajetta E, Nortier JW, et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2001;19:2865–2874. doi: 10.1200/JCO.2001.19.11.2865. [DOI] [PubMed] [Google Scholar]
  • 4.Vansteenkiste J, Pirker R, Massuti B, et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst. 2002;94:1211–1220. doi: 10.1093/jnci/94.16.1211. [DOI] [PubMed] [Google Scholar]
  • 5.Egrie JC, Dwyer E, Browne JK, Hitz A, Lykos MA. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol. 2003;31:290–299. doi: 10.1016/S0301-472X(03)00006-7. [DOI] [PubMed] [Google Scholar]
  • 6.Agoram B, Sutjandra L, Sullivan J. Development and evaluation of a population pharmacokinetic (PK) model for darbepoetin alfa in healthy subjects [abstract].Clin Pharmacol Ther. 2005;77 (suppl S). [DOI] [PMC free article] [PubMed]
  • 7.Heatherington AC, Schuller J, Mercer AJ. Pharmacokinetics of novel erythropoiesis stimulating protein (NESP) in cancer patients: preliminary report. Br J Cancer. 2001;84:11–16. doi: 10.1054/bjoc.2001.1747. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Vadhan-Raj S, Mirtsching B, Charu V, et al. Assessment of hematologic effects and fatigue in cancer patients with chemotherapy-induced anemia given darbepoetin alfa every two weeks. J Support Oncol. 2003;1:131–138. [PubMed] [Google Scholar]
  • 9.Kotasek D, Steger G, Faught W, et al. Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study. Eur J Cancer. 2003;39:2026–2034. doi: 10.1016/S0959-8049(03)00456-8. [DOI] [PubMed] [Google Scholar]
  • 10.Jumbe N, Yao B, Rovetti R, Rossi G, Heatherington AC. Clinical trial simulation of a 200-μg fixed dose of darbepoetin alfa in chemotherapy-induced anemia. Huntingt Libr Q. 2002;16:37–44. [PubMed] [Google Scholar]
  • 11.Hesketh PJ, Arena F, Patel D, et al. A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies. Cancer. 2004;100:859–868. doi: 10.1002/cncr.11954. [DOI] [PubMed] [Google Scholar]
  • 12.Beguin Y, Loo M, R’Zik S, et al. Early prediction of response to recombinant human erythropoietin in patients with the anemia of renal failure by serum transferrin receptor and fibrinogen. Blood. 1993;82:2010–2016. [PubMed] [Google Scholar]
  • 13.Drueke TB. Modulating factors in the hematopoietic response to erythropoietin. Am J Kidney Dis. 1991;18:87–92. [PubMed] [Google Scholar]
  • 14.Beguin Y. Prediction of response to treatment with recombinant human erythropoietin in anaemia associated with cancer. Med Oncol. 1998;15:S38–S46. [PubMed] [Google Scholar]
  • 15.Allon M, Kleinman K, Walczyk M, et al. Pharmacokinetics and pharmacodynamics of darbepoetin alfa and epoetin in patients undergoing dialysis. Clin Pharmacol Ther. 2002;72:546–555. doi: 10.1067/mcp.2002.128374. [DOI] [PubMed] [Google Scholar]
  • 16.Zhang L, Beal SL, Sheiner LB. Simultaneous vs sequential analysis for population PK/PD data I: best-case performance. J Pharmacokinet Pharmacodyn. 2003;30:387–404. doi: 10.1023/B:JOPA.0000012998.04442.1f. [DOI] [PubMed] [Google Scholar]
  • 17.Zhang L, Beal SL, Sheinerz LB. Simultaneous vs sequential analysis for population PK/PD data II: robustness of methods. J Pharmacokinet Pharmacodyn. 2003;30:405–416. doi: 10.1023/B:JOPA.0000012999.36063.4e. [DOI] [PubMed] [Google Scholar]
  • 18.Gastonguay MR. A full model estimation approach for covariate effects: inference based on clinical importance and estimation precision [abstract].AAPS J. 2004;6:
  • 19.Ette EI. Stability and performance of a population pharmacokinetic model. J Clin Pharmacol. 1997;37:486–495. doi: 10.1002/j.1552-4604.1997.tb04326.x. [DOI] [PubMed] [Google Scholar]
  • 20.Burnham KP, Anderson DR. Model Selection and Multimodel Inference: A Practical Information-Theoretic Approach. New York, NY: Springer-Verlag; 2002. [Google Scholar]
  • 21.Derksen S, Keselman HJ. Backward, forward and stepwise automated subset selection algorithms: frequency of obtaining authentic and noise variables. Br J Math Stat Psychol. 1992;45:265–282. [Google Scholar]
  • 22.Harrell FE. Regression Modeling Strategies. New York, NY: Springer; 2001. [Google Scholar]
  • 23.Harrell FE, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361–387. doi: 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4. [DOI] [PubMed] [Google Scholar]
  • 24.Ribbing J, Jonsson EN. Power, selection bias and predictive performance of the Population Pharmacokinetic Covariate Model. J Pharmacokinet Pharmacodyn. 2004;31:109–134. doi: 10.1023/B:JOPA.0000034404.86036.72. [DOI] [PubMed] [Google Scholar]
  • 25.Wahlby U, Jonsson EN, Karlsson MO. Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis. AAPS PharmSci. 2002;4:E27–E27. doi: 10.1208/ps040427. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Dayneka NL, Garg V, Jusko WJ. Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm. 1993;21:457–478. doi: 10.1007/BF01061691. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Friberg LE, Brindley CJ, Karlsson MO, Devlin AJ. Models of schedule dependent haematological toxicity of 2′-deoxy-2′-methylidenecytidine (DMDC) Eur J Clin Pharmacol. 2000;56:567–574. doi: 10.1007/s002280000181. [DOI] [PubMed] [Google Scholar]
  • 28.Gibaldi M, Perrier D. Pharmacokinetics. New York, NY: Marcel Dekker; 1982. [Google Scholar]
  • 29.Wichmann HE, Loeffler M, Pantel K, Wulff H. A mathematical model of erythropoiesis in mice and rats. Part 2: stimulated erythropoiesis. Cell Tissue Kinet. 1989;22:31–49. doi: 10.1111/j.1365-2184.1989.tb00199.x. [DOI] [PubMed] [Google Scholar]
  • 30.Krzyzanski W, Ramakrishnan R, Jusko WJ. Basic pharmacodynamic models for agents that alter production of natural cells. J Pharmacokinet Biopharmaceut. 1999;27:467–489. doi: 10.1023/A:1023249813106. [DOI] [PubMed] [Google Scholar]
  • 31.Loeffler M, Pantel K, Wulff H, Wichmann HE. A mathematical model of erythropoiesis in mice and rats. Part 1: structure of the model. Cell Tissue Kinet. 1989;22:13–30. doi: 10.1111/j.1365-2184.1989.tb00198.x. [DOI] [PubMed] [Google Scholar]
  • 32.Wulff H, Wichmann HE, Pantel K, Loeffler M. A mathematical model of erythropoiesis in mice and rats. Part 3: suppressed erythropoiesis. Cell Tissue Kinet. 1989;22:51–61. doi: 10.1111/j.1365-2184.1989.tb00200.x. [DOI] [PubMed] [Google Scholar]
  • 33.Brockmoller J, Kochling J, Weber W, et al. The pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in haemodialysis patients. Br J Clin Pharmacol. 1992;34:499–508. [PMC free article] [PubMed] [Google Scholar]
  • 34.Uehlinger DE, Gotch FA, Sheiner LB. A pharmacodynamic model of erythropoietin therapy for uremic anemia. Clin Pharmacol Ther. 1992;51:76–89. doi: 10.1038/clpt.1992.10. [DOI] [PubMed] [Google Scholar]
  • 35.Chapel SH, Veng-Pedersen P, Schmidt RL, Widness JA. A pharmacodynamic analysis of erythropoietin-stimulated reticulocyte response in phlebotomized sheep. J Pharmacol Exp Ther. 2000;295:346–351. [PubMed] [Google Scholar]
  • 36.Ramakrishnan R, Cheung WK, Farrell F, Joffee L, Jusko WJ. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after intravenous and subcutaneous dose administration in cynomolgus monkeys. J Pharmacol Exp Ther. 2003;306:324–331. doi: 10.1124/jpet.102.047191. [DOI] [PubMed] [Google Scholar]
  • 37.Ramakrishnan R, Cheung WK, Wacholtz MC, Minton N, Jusko WJ. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after single and multiple doses in healthy volunteers. J Clin Pharmacol. 2004;44:991–1002. doi: 10.1177/0091270004268411. [DOI] [PubMed] [Google Scholar]
  • 38.Macdougall IC, Gray SJ, Elston O, et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol. 1999;10:2392–2395. doi: 10.1681/ASN.V10112392. [DOI] [PubMed] [Google Scholar]
  • 39.Chapel S, Veng-Pedersen P, Hohl RJ, et al. Changes in erythropoietin pharmacokinetics following busulfan-induced bone marrow ablation in sheep: evidence for bone marrow as a major erythropoietin elimination pathway. J Pharmacol Exp Ther. 2001;298:820–824. [PubMed] [Google Scholar]
  • 40.Piroso E, Erslev AJ, Flaharty KK, Caro J. Erythropoietin life span in rats with hypoplastic and hyperplastic bone marrows. Am J Hematol. 1991;36:105–110. doi: 10.1002/ajh.2830360208. [DOI] [PubMed] [Google Scholar]
  • 41.Glaspy J, Henry D, Patel R, et al. The effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: a randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa. Eur J Cancer. 2005;41:1140–1149. doi: 10.1016/j.ejca.2005.01.021. [DOI] [PubMed] [Google Scholar]
  • 42.Heatherington AC, Henry D, Patel R, et al. The impact of timing of chemotherapy relative to darbepoetin alfa (DA) on DA pharmacokinetics (PK) and hematologic effects [abstract].Clin Pharmacol Ther. 2004;75:
  • 43.Mercadante S, Gebbia V, Marrazzo A, Filosto S. Anaemia in cancer: pathophysiology and treatment. Cancer Treat Rev. 2000;26:303–311. doi: 10.1053/ctrv.2000.0181. [DOI] [PubMed] [Google Scholar]
  • 44.Bentler E, Lichtman MA, Coller BS, Kipps TJ. Williams Hematology. New York, NY: McGraw-Hill Inc.; 1995. [Google Scholar]
  • 45.Mahaffy JM, Belair J, Mackey MC. Hematopoietic model with moving boundary condition and state dependent delay: applications in erythropoiesis. J Theor Biol. 1998;190:135–146. doi: 10.1006/jtbi.1997.0537. [DOI] [PubMed] [Google Scholar]
  • 46.Krzyzanski W, Jusko WJ, Wacholtz MC, Minton N, Cheung WK. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after multiple subcutaneous doses in healthy subjects. Eur J Pharm Sci. 2005;26:295–306. doi: 10.1016/j.ejps.2005.06.010. [DOI] [PubMed] [Google Scholar]
  • 47.Amgen Inc . Aranesp (Darbepoetin alfa) Summary of Product Characteristics. Breda, The Netherlands: Amgen Inc; 2005. [Google Scholar]
  • 48.Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet. 2003;362:1255–1260. doi: 10.1016/S0140-6736(03)14567-9. [DOI] [PubMed] [Google Scholar]
  • 49.Leyland-Jones B. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol. 2003;4:459–460. doi: 10.1016/S1470-2045(03)01163-X. [DOI] [PubMed] [Google Scholar]

Articles from The AAPS Journal are provided here courtesy of American Association of Pharmaceutical Scientists

RESOURCES